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BACKGROUND: Oestrogen receptor-alpha (ERa) is highly expressed in diffuse-type gastric cancer and oestrogen increases the
proliferation of ERa-positive gastric cancer. However, a detailed mechanism by which oestrogen increases the proliferation of these
cells is still unclear.
METHODS: We used 17-b-oestradiol (E2) as a stimulator against the ERa pathway. Pure anti-oestrogen drug ICI 182780 (ICI) and
small interfering RNA against ERa (ERa siRNA) were used as inhibitors. Cyclopamine (Cyc) was used as the hedgehog (Hh) pathway
inhibitor. Two human ERa-positive gastric cancer cells were used as target cells. Effects of the stimulator and inhibitor on E2-induced
cell proliferation were also examined.
RESULTS:I nE R a-positive cells, E2 increased not only cell proliferation but also one of the ligands of the Hh pathway, Shh expression.
17-b-Oestradiol-induced cell proliferation was suppressed by ICI, ERa siRNA or Cyc. The increased expression of Shh induced by E2
was suppressed by ICI and ERa siRNA but not by Cyc. Furthermore, recombinant Shh activated the Hh pathway and increased cell
proliferation, whereas anti-Shh antibody suppressed E2-induced cell proliferation. When a relationship between ERa and Shh
expressions was analysed using surgically resected gastric cancer specimens, a positive correlation was found, suggesting a linkage
between the ERa and Hh pathways.
CONCLUSION: Our data indicate that activation of the ERa pathway promotes cell proliferation by activating the Hh pathway in a
ligand-dependent manner through Shh induction of ERa-positive gastric cancer.
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Gastric cancer is one of the most lethal of all malignancies (Parkin,
2001). In particular, patients with unresectable, metastatic or
recurrent gastric cancer have only few therapeutic options. Thus, it
is urgent to develop novel therapeutics for gastric cancer.
Gastric cancers are classified into two major histological types
using the criteria of Lauren, namely intestinal type and diffuse type
(Lauren, 1965). The carcinogenic pathway of intestinal-type
gastric cancer develops through several sequential stages with
Helicobacter pylori infection, followed by chronic gastritis,
atrophic gastritis and intestinal metaplasia (Yuasa, 2003), whereas
the diffuse type is believed to be derived from hyperplastic stem or
precursor cells (Ming, 1998). It is considered that diffuse-type
gastric cancer has a higher malignant potential such as invasion
and metastasis, compared with intestinal-type gastric cancer.
Oestrogen has various physiological functions, such as normal
cell growth and differentiation in many target tissues. Oestrogen is
produced not only from the ovary but also from extra-ovarian
tissues, that is, from the skin, brain, testis, adipose tissues and
vascular smooth muscle (Ackerman et al, 1981; Leshin et al, 1981;
Brodie and Inkster, 1993; Lephart, 1996; Ueyama et al, 2002). The
biological actions of oestrogen are mediated through two specific
receptors (oestrogen receptor, ERs), ERa and ERb, which belong to
the nuclear receptor superfamily. Oestrogen-bound ERs bind as
homodimers or heterodimers to a specific DNA sequence known
as the oestrogen-responsive element (ERE), and regulate the
transcription of target genes (Matthews and Gustafsson, 2003). As
oestrogen is a stimulant for the initiation and promotion of breast
cancer, and ERa can be expressed in gastric cancer cells, it has
been suggested that the ERa pathway may have a role in the
progression of gastric cancer (Harrison et al, 1989b; Wu et al,
1994; Karat et al, 1999; Takano et al, 2002; Chandanos et al, 2008).
In gastric cancer, ERa expression is higher in the diffuse
type than in the intestinal type (Kitaoka, 1983; Tokunaga et al,
1986; Matsui et al, 1992; Zhao et al, 2003), and oestradiol (E2)
enhances gastric cancer cell proliferation in vitro (Matsui et al,
1992; Takano et al, 2002). On the basis of these observations,
several clinical trials using a partial oestrogen antagonist,
tamoxifen (TAM), have been conducted for the management of
ERa-positive gastric cancer patients. However, the results have
not been consistent and the utility of ERa for the treatment of
gastric cancer is still controversial (Harrison et al, 1989a,b;
Koullias et al, 2003).
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sThe hedgehog (Hh) signalling pathway has a crucial role in
embryonic development, tissue regeneration and carcinogenesis. Of
the three Hh ligands, namely Sonic Hh (Shh), Indian Hh (Ihh)a n d
Desert Hh (Dhh) (Pasca di Magliano and Hebrok, 2003; Lum and
Beachy, 2004; Briscoe and Therond, 2005; Hooper and Scott, 2005;
Katoh and Katoh, 2005), Shh is exclusively expressed in the acid-
producing parietal cells in both human and murine stomach, and is
believed to be a regulator of gastric fundic gland differentiation and
mutation (Ramalho-Santos et al, 2000; van den Brink et al, 2001,
2002; Dimmler et al, 2003). Pharmacological inhibition of Shh
signalling in the adult stomach causes loss of parietal cells (gastric
atrophy) and subsequent disruption of glandular differentiation (van
den Brink et al, 2002). Furthermore, Shh is strongly implicated in
maintaining stem cell niches in the adult stomach (Katoh and Katoh,
2006). Recently, ligand-dependent activation of the Hh pathway,
especially due to an aberrant expression of Shh, has been detected in
various cancers including gastric cancer (Berman et al, 2003; Watkins
et al, 2003; Karhadkar et al, 2004; Sanchez et al, 2004; Sheng et al,
2004). Overexpression of Shh leads to carcinogenesis through the
aberrant activation of the Hh pathway (Berman et al, 2003; Thayer
et al, 2003; Cengel, 2004; Sanchez et al, 2004). It is also believed that
Shh has an important role during the progression of gastric cancer,
because Shh expression is much higher in the diffuse type than in the
intestinal type in human gastric cancer (Ma et al, 2005, 2006).
It is noteworthy that our previous study demonstrated a positive
correlation between Hh pathway activation and ERa status (Kubo
et al, 2004), and suggested that ERa could regulate Hh pathway
activation in ERa-positive breast cancer (Koga et al, 2008). It has also
been shown that the Hh pathway can be a useful therapeutic target
against breast cancer and gastric cancer (Kubo et al, 2004; Yanai
et al, 2007). From these results, we hypothesised that stimulation of
the ERa pathway induces Shh expression, activates the Hh pathway
and consequently promotes cell proliferation in ERa-positive gastric
cancer cells. The ERa pathway could be a possible therapeutic target
for patients with ERa-positive gastric cancer.
MATERIALS AND METHODS
Cell culture, reagents and antibodies
We prepared eight gastric cancer cell lines, KATOIII, NCI-N87,
MK-1, AGS, MKN45, Hs746T, SNU-16 and MKN74. These were
maintained at 371C under a humidified atmosphere of 5% CO2 and
95% air in RPMI1640 medium (Life Technologies, Grand Island,
NY, USA) supplemented with 10% fetal bovine serum (FBS; Life
Technologies) and antibiotics (100Unitsml
 1 penicillin and
100mgml
 1 streptomycin; Meijiseika, Tokyo, Japan). Cells were
incubated for 24h in phenol-red-free minimum essential medium
(MEM; Invitrogen, Carlsbad, CA, USA) without FBS before all
experiments (termed oestrogen starvation). Thereafter, cells were
principally cultured in MEM supplemented with 5% dextran-
coated charcoal-treated FBS (DCC-FBS-MEM) in a humidified 95%
air and 5% CO2 atmosphere. 17-b-Oestradiol was purchased from
Sigma (Deisenhofen, Germany). The ER pathway antagonist, ICI
182780 (ICI), was purchased from Tocris Cookson Ltd. (Ellisville,
MO, USA). Cyclopamine (Cyc) was purchased from Toronto
Research Chemicals (North York, ON, Canada). Both ICI and Cyc
were diluted in 99.5% ethanol as a stock solution, and stored at
 301C. Recombinant human Shh N-terminal peptide (rhShh) was
purchased from R&D Systems (Minneapolis, MN, USA). Rat anti-
Shh NH2-terminal peptide antibody (aShh-Ab) was purchased
from R&D Systems.
Expression vectors
cDNAs encoding human ERa were cloned into the pSG5
expression vector as described previously (Green et al, 1988; Kato
et al, 2002). This cDNA and ERE-tk-luc, a single consensus ERE
upstream of luciferase, were kindly provided by Dr Norio Wake
(Kyushu University, Fukuoka, Japan). pRL-SV40 was purchased
from Promega (Madison, WI, USA).
Reverse transcription–PCR
Total RNA was extracted from cultured cells by the guanidinium
thiocyanate–phenol–chloroform single-step method. For the
reverse transcription (RT) reaction, pd(N)6 Random Hexamer
(GE Healthcare UK Ltd, Buckinghamshire, England) was used for
priming. The ERa forward (50-CAG GGG TGA GTG GGG TC-30)
and reverse (50-ATG CGG AAC CGA GAT GAT-30) primers yielded
a 483-bp product. Gli1 forward (50-TCT GCC CCC ATT GCC CAC
TTG-30) and reverse (50-TAC ATA GCC CCC AGC TAC CTC-30)
primers yielded a 480-bp product. The Shh forward (50-CGC ACG
GGG ACA GCT CGG AAG T-30) and reverse (50-CTG CGC GGC
CCT CGT AGT GC-30) primers yielded a 477-bp product. The
Ptch1 forward (50-CGG CGT TCT CAA TGG GCT GGT TTT-30) and
reverse (50-GTG GGG CTG CTG TCT CGG GTT CG-30) primers
yielded a 376-bp product. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) forward (50-CCA CCC ATG GCA AAT TCC
ATG GCA-30) and reverse (50-TCT AGA CGG CAG GTC AGG TCC
ACC-30) primers yielded a 593-bp product. The amplification
conditions comprised an initial denaturation for 2min at 951C,
followed by 35 cycles of 941C for 30s, 581Cf o r3 0 sa n d7 2 1Cf o r
1min. The amplification of each gene was in the linear range. The
RT–PCR products were separated on ethidium bromide-stained 2%
agarose gels. Semi-quantitative analysis was carried out with a
Molecular Imager FX Pro (Bio-Rad Laboratories, Hercules, CA, USA).
Real-time RT–PCR
Total RNA was extracted using the RNeasy mini kit (Qiagen,
Valencia, CA, USA) and quantified by spectrophotometry
(Ultrospec 2100 Pro; Amersham Pharmacia Biotech, Cambridge,
UK). RNA (700ng) was treated with DNase, and reverse transcribed
to cDNA using the Quantitect Reverse Transcription Kit (Qiagen)
according to the manufacturer’s protocol. Reactions were run with
SYBR Premix Ex Taq (Takara Bio Inc., Otsu, Japan) on a DNA
Engine Opticon 2 System (MJ Research, Waltham, MA, USA). pShh-
GFP or pGli1 was serially diluted in 10-fold increments and
amplified with the primer pairs to generate a standard curve for Shh
or Gli1. Standard curves for b-actin were generated using cDNA
from MK-1 cells treated with E2 for 8h. Each sample was run in
triplicate. All primer sets amplified fragments o200bp long. The
sequences of the primers used were as follows: b-actin,f o r w a r d ,
50-TTG CCG ACA GGA TGC AGA AGG A-30,r e v e r s e ,5 0-AGG TGG
ACA GCG AGG CCA GGA T-30; ERa,f o r w a r d ,5 0-GGA GGG CAG
GGG TGA A-30,r e v e r s e ,5 0-GGC CAG GCT GTT CTT CTT AG-30;
pS2,f o r w a r d ,5 0-CAT GGA CGT CCC TCC AGA AGA G-30,r e v e r s e ,
50-CTC TGG GAC TAA TCA CCG TGC TG-30; Shh,f o r w a r d ,5 0-GTG
TAC TAC GAG TCC AAG GCA C-30,r e v e r s e ,5 0-AGG AAG TCG
CTG TAG AGC AGC-30;a n dGli1,f o r w a r d ,5 0-GGT TCA AGA GCC
TGG GCT GTG T-30,r e v e r s e ,5 0-GGC AGC ATT CTC AGT GAT GCT
G-30. The amount of each target gene in a given sample was
normalised to the level of b-actin in that sample.
Immunoblotting
Whole-cell extraction was performed with M-PER Reagents (Pierce
Biotechnology, Rockford, IL, USA) according to the manufac-
turer’s instructions. Protein concentration was determined using
the Bio-Rad Protein Assay (Bio-Rad Laboratories), and whole-cell
extract (80mg) was separated by electrophoresis on a SDS-
polyacrylamide gel, and transferred to Protran nitrocellulose
membranes (Whatman, Dassel, Germany). Blots were then
incubated overnight with GAPDH (1:1000), ERa (1:200) or Shh
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HRP-linked secondary antibody (Amersham Biosciences, Piscat-
away, NJ, USA) at room temperature for 1h. Immunocomplexes
were detected using ECL together with the western blotting
detection system (Amersham Biosciences) and visualised using a
Molecular Imager FX (Bio-Rad Laboratories). Glyceraldehyde-3-
phosphate dehydrogenase was used as a protein loading control.
Dual luciferase assay
KATOIII and NCI-N87 cells in 24-well plates were transfected with
plasmids with TransFast transfection reagent according to the
manufacturer’s instructions. Cells on each well were co-transfected
with 10ng of pRL-SV40 (Promega) and 1mg ERE-tk-Luc. After
oestrogen starvation, E2 and ICI or Cyc were added to each well for
8h, and luciferase assays were performed using the dual luciferase
assay kit (Promega) according to the manufacturer’s instructions.
The luciferase activities were normalised to Renilla luciferase
activity.
Small interfering RNA against ERa
KATOIII and NCI-N87 cells (1.0 10
6 cells) were transfected with
small interfering RNA (siRNA) (100nM) against ERa by lipofecta-
mine as per the manufacturer’s instructions, and then plated in a
25-cm
2 flask for 24h in 10% FBS-RPMI. After oestrogen starvation,
the cells were treated with E2 for 16h, and then used for real-time
RT–PCR. The following siRNAs were used: Validated Stealth RNAi
against ERa and the Stealth RNAi-negative control (Invitrogen).
Proliferation assay
KATOIII (5 10
3 per well), NCI-N87 (1 10
4 per well) and MK-1
(5 10
3 per well) cells were seeded in 48-well plates in complete
culture medium and were incubated overnight. After oestrogen
starvation, the medium was changed to 5% DCC-FBS-MEM
containing various concentrations of reagents. After 72h of
incubation, cells were harvested by trypsinisation, and viable cells
were counted using a Coulter counter (Beckman Coulter, Fullerton,
CA, USA).
Clinical samples
Surgical specimens were obtained from 20 patients with diffuse-
type gastric cancer and from 20 patients with intestinal type. All of
the patients underwent resection at the Department of Surgery and
Oncology, Kyushu University (Fukuoka, Japan), between 1996 and
2004. All 40 patients gave informed consent before surgical
treatment and were enrolled into this study. All surgical specimens
were frozen at  801C, examined histopathologically and classified
using the tumour-node-metastasis classification. Total mRNA of
these specimens was extracted using the RNeasy mini kit (Qiagen)
as per the manufacturer’s recommendation.
Immunohistochemistry
Single-antibody detection was carried out as described previously
(Kubo et al, 2004), with the following protocol modifications:
Endogenous peroxidase activity was blocked using 3% H2O2 in
methanol for 30min at room temperature. Antigen retrieval was
achieved by boiling tissue in 0.01moll
 1 sodium citrate (pH 6.0)
for 5min. All primary antibodies were incubated overnight at 41C.
The primary antibodies used were Shh (1:50 H-160, sc-9024,) and
ERa (1:50 F-10, sc-8002) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Secondary antibodies (Shh rabbit anti-IgG; ERa, mouse
anti-IgG; Nichirei Co., Ltd, Tokyo, Japan) were applied for 1h at
room temperature. Protein was detected by brown pigmentation
using the standard 3, 30-diaminobenzidine (DAB) protocol. Slides
were lightly counterstained with haematoxylin. Negative controls
were obtained in all cases by omitting the first antibodies. All primary
antibodies had been previously tested for immunohistostaining.
Statistical analysis
Student’s t-test was used for statistical analysis, unless indicated
otherwise. The correlation of clinicopathological features between
the ERa and Shh expression was analysed by the Mann–Whitney
U-test. All calculations were carried out using the StatView 5.0 J
software (Abacus Concepts, Berkeley, CA, USA). Single asterisk
denotes Po0.05; P-values o0.05 were considered significant.
RESULTS
Oestrogen activates the ERa pathway and induces
increased proliferation
We examined ERa expression in eight human gastric cancer cell
lines. Five cell lines showed ERa expression at the mRNA level
(Figure 1A), and three of the five cell lines, namely KATOIII, NCI-
N87 and AGS cells, also showed detectable ERa expression at the
protein level (Figure 1A). Thus, we selected KATOIII (diffuse type)
and NCI-N87 (intestinal type) cells as ERa-positive cells, and
selected MK-1 cells (diffuse type) as ERa-negative cells. We then
examined whether the ERa pathway has a role in the proliferation
of ERa-positive cells. As we expected, E2 increased the prolifera-
tion of ERa-positive but not negative cells in a dose-dependent
manner (Figure 1B). This E2-induced cell proliferation was
completely inhibited by ICI 182780 (100nM). ICI did not affect
cell proliferation without supplementation of E2 (Figure 1B). On
the basis of these preliminary data, E2 and ICI were used at a
concentration of 3 and 100nM, respectively, throughout the study.
We further examined whether the ERa pathway is functional in
these ERa-positive cells. Activation of the ERa pathway by E2 was
determined with an ERa reporter assay and pS2 expression, a
target gene of the ERa pathway (Campbell-Thompson, 1997; Singh
et al, 1997). We found that E2 increased both ERa-responsive
reporter activity (Figure 1C) and pS2 mRNA expression
(Figure 1C) in these ERa-positive cells. This increased activation
of the ERa pathway by E2 was almost completely inhibited by ICI.
Finally, to confirm the contribution of the ERa pathway to
E2-induced proliferation of ERa-positive cells, we silenced ERa mRNA
expression of ERa-positive cells by RNA interference. Transfection
of siRNA resulted in an 85% or greater knockdown of ERa mRNA
expression (data not shown). Silencing of ERa did not affect cell
proliferation without supplementation of E2. However, E2-induced
cell proliferation was inhibited by ERa-siRNA (Figure 1D). These
data indicate that E2 increases proliferation of ERa-positive gastric
cancer cells through activation of the ERa pathway.
Oestrogen-induced cell proliferation is suppressed by
inhibition of the Hh pathway
As our previous study indicated a crosstalk between the ERa and
Hh pathways in ERa-positive breast cancer cells (Koga et al, 2008),
we examined the expression of Hh-related molecules, including
Shh, Ptched 1 (Ptc) and Gli1, in ERa-positive gastric cancer cells.
Consistent with our previous report (Yanai et al, 2007), we found
that these cells expressed Hh-related molecules at the mRNA level
(Figure 2A). Gli1 expression indicates a constitutive activation of
the Hh pathway in gastric cancer cells, because Gli1 is a target gene
of the Hh pathway (Kubo et al, 2004). In our previous report,
cyclopamine suppressed the proliferation of these cells (Yanai
et al, 2007). To estimate a contribution of the Hh pathway to
E2-induced increase in proliferation, we compared the increasing
rate of proliferation induced by E2 between the presence and
absence of Hh pathway activity (Figure 2B). In Kato III, the
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Figure 1 E2 activates the ERa pathway and induces increased proliferation in ERa-positive gastric cancer cells. (A) Both mRNA (upper panel) and protein
(lower panel) expression of ERa were increased in KATOIII and NCI-N87, as shown by RT–PCR and western blotting. GAPDH was used as a loading
control. (B) Cell proliferation in the presence of E2 alone (upper panel) or in combination with ICI (lower panel) in KATOIII, NCI-N87 and MK-1 cells. Cells
were cultured in 5% DCC-FBS-MEM (DCC-FBS) for 72h. (C) A dual luciferase assay was performed 8h after treatment with the indicated reagents (left
two panels). Relative pS2 mRNA expression in KATOIII and NCI-N87 was examined by real-time RT–PCR (right two panels). (D) Cell proliferation in
KATOIII and NCI-N87 cells transfected with ERa-siRNAs or control siRNA. After transfection with ERa siRNA or control siRNA, KATOIII and NCI-N87
cells were treated with or without E2 for 72h. Results are expressed as mean±s.d. *Po0.05.
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sincreasing rate was 28 and 18% in the presence and absence of Hh
pathway activity, respectively. In NCI-N87, it was 35 and 22%,
respectively. These data indicate that a block of the Hh pathway
reduces the degree of E2-induced increase of proliferation. To
determine the relationship between these two pathways, we
examined how cyclopamine affects ERa pathway activation
induced by E2. We found that cyclopamine did not affect E2-
induced activation of the ERa pathway (Figure 2C). These data
suggest that the Hh pathway contributes to E2-induced cell
proliferation of ERa-positive gastric cancer cells.
Oestrogen induces the increased Shh expression through
activation of the ERa pathway
As contribution of the Hh pathway to E2-induced cell proliferation
has been previously suggested, we examined whether E2 could
induce Hh pathway activation in ERa-positive cells. Activation of
the Hh pathway was determined by Gli1 mRNA expression. We
found that E2 markedly increased Gli1 mRNA expression in ERa-
positive cells, and that the increased Gli1 mRNA expression was
significantly suppressed by ICI. ICI alone did not affect Gli1 mRNA
expression without supplementation of E2 (Figure 3A). Cyclopa-
mine suppressed this E2-induced Gli1 mRNA expression more
strongly than did ICI. 17-b-Oestradiol-induced Gli1 mRNA
expression was not found in ERa-negative cells. We then
investigated the molecular mechanisms by which E2 activates the
Hh pathway in ERa-positive cells. Ligand-dependent activation of
the Hh pathway has been shown in gastric cancer (Berman et al,
2003). Therefore, we focused on an Hh pathway ligand, Shh. As
expected, E2 increased Shh mRNA expression of ERa-positive cells,
and this E2-induced increase was almost completely inhibited by
ICI (Figure 3B). Cyclopamine did not affect E2-induced Shh
expression. Neither ICI nor cyclopamine significantly affected Shh
expression in ERa-negative cells. Finally, to confirm a contribution
of the ERa pathway to E2-induced Shh mRNA expression in ERa-
positive cells, we used ERa-silenced ERa-positive cells as target
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scells. Silencing of ERa alone did not affect Shh expression when
there was no supplementation of E2. Importantly, E2-induced Shh
expression was almost completely inhibited in ERa-silencing cells
(Figure 3C). These data indicate that E2 increases Shh induction of
ERa-positive gastric cancer cells through the activation of the ERa
pathway.
Oestrogen increases cell proliferation through Shh
induction, followed by increased Hh pathway activation
We next examined whether Shh induced by E2 could cause the
proliferation of ERa-positive cells in a ligand-dependent manner.
As mentioned above, the Hh pathway is constitutively activated in
these cells. Therefore, we first investigated whether exogenous Shh
could further increase the proliferation of these cells. We found
that rhShh increased Gli1 mRNA expression (data not shown) and
the proliferation of these ERa-positive cells in a dose-dependent
manner (Figure 4A). We investigated whether a neutralising
antibody against Shh could suppress E2-induced proliferation of
ERa-positive cells. Anti-Shh antibody decreased Gli1 mRNA
expression (data not shown). Anti-Shh antibody reduced the
increasing rate of proliferation induced by E2 (Figure 4B). In
KATO III, the increasing rate was 2 and 33% in the presence and
absence of the anti-Shh antibody, respectively. In NCI-N87, it was
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Figure 3 E2 upregulates Shh expression through ERa activation in ERa-positive gastric cancer cells. (A) Gli1 mRNA in KATOIII, NCI-N87 and MK-1 cells
treated with the indicated reagents for 8h was examined by real-time RT-PCR. (B) Shh mRNA in KATOIII, NCI-N87 and MK-1 cells treated with the
indicated reagents for 8h was examined by real-time RT-PCR. (C) After transfection with ERa siRNA or control siRNA, KATOIII and NCI-N87 cells were
treated with E2 for 8h and then Shh mRNA was examined by real-time RT–PCR. Results are expressed as mean±s.d. *Po0.05.
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s36 and 42%, respectively. These data indicate that the anti-Shh
antibody reduces the degree of E2-induced increase of prolifera-
tion, suggesting a contribution of Shh to E2-induced proliferation.
Taken together, these results suggest that Shh induced by E2 is
functional and increases cell proliferation by activating the Hh
pathway in a ligand-dependent manner.
ERa mRNA expression positively correlates with Shh
mRNA expression in gastric cancer tissues
We investigated the possibility that a correlation between the ERa
and Hh pathways exists in vivo using 40 surgically resected gastric
cancer tissues. When 40 gastric cancer tissues were histologically
divided into two groups, that is, 20 diffuse type and 20 intestinal
type, no significant correlation between histological type and UICC
stage was found (data not shown). The ERa mRNA expression was
significantly higher in diffuse-type gastric cancer tissues than in
intestinal-type gastric cancer tissues (Po0.0001; Figure 5A).
Similarly, Shh mRNA expression was significantly higher in
diffuse-type gastric cancer tissues than in intestinal-type gastric
cancer tissues (Po0.016; Figure 5A). As expected, mRNA
expression levels of ERa and Shh were tightly correlated
(Po0.0001; Figure 5B). The correlation between ERa and Shh is
significantly stronger in diffuse-type (Po0.0001; Supplementary
Figure 1A) gastric cancer tissues than in intestinal-type gastric
cancer tissues (Po0.0226; Supplementary Figure 1B). Expression
of ERa and Shh was also examined immunohistochemically.
Consistent with mRNA expression, both ERa and Shh were also
highly expressed in diffuse-type gastric cancer cells (Figure 5C). In
addition, histochemical analysis showed that Shh is mainly
expressed by cancer cells themselves. In this study, however, we
did not perform correlation analysis between these molecules at
the protein level, because it was difficult to accurately estimate the
expression intensity. Nevertheless, our data suggest that a novel
link between the ERa and Hh pathways is present even in gastric
cancer tissues.
DISCUSSION
We have shown, for the first time, a biologically significant linkage
between the ERa and Hh pathways in ERa-positive gastric cancer
cells. Briefly, oestrogen activates the ERa pathway, induces Shh
production, activates Hh activation in an Shh-dependent manner
and consequently increases cell proliferation in ERa-positive
gastric cancer cells. Our data suggest that the ERa pathway could
be a possible therapeutic target for patients with ERa-positive
gastric cancer.
Consistent with our present data, it has already been shown that
both ERa (Kitaoka, 1983; Tokunaga et al, 1986; Matsui et al, 1992;
Zhao et al, 2003) and Shh (Ma et al, 2005; Yanai et al, 2007) are
frequently expressed in diffuse-type gastric cancer, compared with
intestinal type. Recently, it was shown that the Hh pathway might
be linked to other proliferation-related signalling pathways. We
have shown a crosstalk of the Hh pathway with the nuclear factor
k-B pathway in pancreatic cancer (Nakashima et al, 2006), the Wnt
pathway in colonic and gastric cancer (Akiyoshi et al, 2008; Yanai
et al, 2008) and the ERa pathway in breast cancer (Koga et al,
2008). Thus, we speculated that there was a linkage between the
ERa and Hh pathways in diffuse-type gastric cancer. Our present
data showed two key points in the linkage between the two
pathways. One finding is that the ERa pathway affects the Hh
pathway, because E2 induces both ERa pathway activation and Shh
induction, followed by Hh pathway activation, and all of these
phenomena were almost completely suppressed by blockade of the
ERa pathway. The other finding is that the Hh pathway does not
affect the ERa pathway, because neither blockade nor stimulation
of the Hh pathway affected ERa pathway activation. A key
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Figure 4 E2 increases cell proliferation through Shh induction, followed by increased Hh pathway activation. (A) KATOIII and NCI-N87 cells were
treated with rhShh at the indicated concentrations for 72h. rhShh was resolved in PBS containing 0.1% bovine serum albumin (BSA) as per the
manufacturer’s recommendation. Each control contained the same amount of BSA. Results are expressed as percentage (%) cell number to each control.
(B) Cells were treated with anti-Shh antibody (aShh-Ab, 30mgml
 1) or isotype-matched control IgG (Control IgG, 30mgml
 1) in the presence of E2 in
KATOIII and NCI-N87 cells for 72h. aShh-Ab or control IgG was added to the medium at the same time as E2. The increasing rate of proliferation induced
by E2 in the presence and absence of aShh antibody is expressed as mean±s.d. *Po0.05.
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smolecule linking the ERa pathway with the Hh pathway is Shh,
which is induced by ERa pathway activation. Thus, we speculate
that a crosstalk between the two pathways is a one-way link
from the ERa to the Hh pathway. The molecular mechanisms by
which ERa pathway activation induces Shh production remain
unclear.
Ligand-dependent Hh pathway activation participates in the
increased proliferation of gastric cancer (Berman et al, 2003; Yanai
et al, 2007). Therefore, in our study, it is not surprising that
oestrogen-induced Shh induction increased the proliferation of
ERa-positive gastric cancer cells. Our data indicate that blockade
of the ERa pathway, such as using anti-oestrogens, may be valuable
therapeutic tools for patients with ERa-positive gastric cancer.
Interestingly, several clinical randomised controlled studies have
already been performed using the selective ER modulator, TAM.
Although ER status is an independent poor prognostic factor in
gastric cancer (Harrison et al, 1989b; Matsui et al, 1992), the
results of clinical randomised controlled studies disappointed us
(Harrison et al, 1989a,b). Nevertheless, our present data still
indicate a possibility of an ERa pathway blocker as a therapeutic
tool for patients with ERa-positive gastric cancer. When TAM was
used at concentrations (1mM) that do not affect cell proliferation of
ERa-negative MK-1 cells (Supplementary Figure 2B), TAM did
not significantly suppress both E2-induced Hh activation and
E2-induced cell proliferation of ERa-positive gastric cancer cells
(Supplementary Figure 2A). In contrast, ICI, at a concentration
(100nM) that does not affect cell proliferation of MK-1cells, almost
completely suppressed both E2-induced Hh activation and E2-
induced cell proliferation. It is well known that TAM can block
only one domain, that is, activating function 2 (AF-2), among two
distinct ERa activation domains (Ali and Coombes, 2002), whereas
ICI can block both of the activation domains. In addition, it has
been reported that TAM seems to function as a partial agonist in
uterine tissues (Kedar et al, 1994). These findings indicate a
possibility that different anti-oestrogens may display different
tissue-specific actions. Our data indicate that the development of
clinically available antagonists that can sufficiently block oestro-
gen-induced cell proliferation is promising for management of
patients with aggressive diffuse-type gastric cancer. Our data also
indicate that a combination of Hh inhibitors and anti-oestrogens
may be more effective against ERa-positive gastric cancer.
Furthermore, molecules contributing to E2-induced Shh induction
may be novel therapeutic candidate molecules for the management
of gastric cancer patients.
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